Efficacy of HIPEC as NACT and Postoperative Chemotherapy in the Treatment of Advanced-Stage Epithelial Ovarian Cancer

• Status: Not yet recruiting
• Trial end date: 2022-07-01

Summary

This project is a multi-center, prospective, randomized controlled clinical observation the safety and efficacy of hyperthermic intraperitoneal chemotherapy as neoadjuvant chemotherapy(NACT) and postoperative chemotherapy after interval debulking surgery (IDS) for advanced-stage epithelial ovarian cancer . PR/SD rate, percentage of optimal debulking surgery and 3-year disease-free survival is the primary end points of this project.

• Phase: Phase 3

Details

• Lead Sponsor: Shu-Zhong Cui
• Collaborators: Beijing Cancer Hospital; Beijing Obstetrics and Gynecology Hospital; Cancer Hospital of Guizhou Province; Chinese PLA General Hospital; Chongqing Cancer Institute; First Affiliated Hospital, Sun Yat-Sen University; Fourth Affiliated Hospital of Guangxi Medical University; Hebei Medical University Fourth Hospital; Henan Cancer Hospital; Henan Provincial Hospital; Henan Provincial People's Hospital; Obstetrics & Gynecology Hospital of Fudan University; Peking Union Medical College Hospital; Peking University People's Hospital; RenJi Hospital; Shandong Cancer Hospital and Institute; Southern Medical University, China; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; The Second Hospital of Hebei Medical University; The Third Affiliated Hospital of Guangzhou Medical University; The Third Xiangya Hospital of Central South University; Third Affiliated Hospital, Sun Yat-Sen University; Tianjin Medical University Cancer Institute and Hospital; West China Second University Hospital; Wuhan Union Hospital, China; Wuhan University; Xiangya Hospital of Central South University; Xinqiao Hospital of Chongqing
• Treatments: Albumin-Bound Paclitaxel; Carboplatin; Paclitaxel